Galectin Therapeutics (GALT) EPS (Weighted Average and Diluted) (2020 - 2026)
Galectin Therapeutics' quarterly EPS (Weighted Average and Diluted) came in at -$0.08 in Q1 2026, up 46.67% year-on-year from -$0.05 in Q1 2025, and little changed quarter-over-quarter from -$0.08 in Q4 2025.
Galectin Therapeutics has reported EPS (Weighted Average and Diluted) for 7 years, with the latest figure at -$0.08 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 46.67% year-over-year to -$0.08; the trailing twelve-month figure through Mar 2026 stood at -$0.41 (up 43.06% YoY), and the FY2025 full-year result was -$0.48, up 36.84% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.08, roughly flat from -$0.08 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was -$0.08 in Q4 2025, with the low at -$0.24 in Q3 2023.
- Average EPS (Weighted Average and Diluted) over 5 years is -$0.16, with a median of -$0.16 recorded in 2023.
- Year-over-year, EPS (Weighted Average and Diluted) plunged 71.43% in 2023 and surged 57.89% in 2025.
- Tracing GALT's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.18 in 2022, then gained by 11.11% to -$0.16 in 2023, then declined by 18.75% to -$0.19 in 2024, then surged by 57.89% to -$0.08 in 2025, then decreased by 0.0% to -$0.08 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.08 (Q1 2026), -$0.08 (Q4 2025), and -$0.13 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.51 |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | -0.08 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.08 |
| Dec 31, 2025 | -0.08 |
| Sep 30, 2025 | -0.13 |
| Jun 30, 2025 | -0.12 |
| Mar 31, 2025 | -0.15 |
| Dec 31, 2024 | -0.19 |
| Sep 30, 2024 | -0.18 |
| Jun 30, 2024 | -0.20 |
| Mar 31, 2024 | -0.19 |
| Dec 31, 2023 | -0.16 |
| Sep 30, 2023 | -0.24 |
| Jun 30, 2023 | -0.15 |
| Mar 31, 2023 | -0.19 |
| Dec 31, 2022 | -0.18 |
| Sep 30, 2022 | -0.14 |
| Jun 30, 2022 | -0.16 |
| Mar 31, 2022 | -0.17 |
| Dec 31, 2021 | -0.12 |
| Sep 30, 2021 | -0.14 |
| Jun 30, 2021 | -0.15 |
| Mar 31, 2021 | -0.11 |
| Dec 31, 2020 | -0.13 |
| Sep 30, 2020 | -0.10 |